Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in advanced solid tumors (umbrella study)
NCT06612632Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in solid tumor (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Number of Participants Experiencing Adverse Events at 5 years, Number of Participants Experiencing Treatment-Emergent Adverse Events at 5 years and 2 more. Started May 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06612632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612632.